secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-060237
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q3 revenue $25.4M, net loss $21M; raises outlook, merger with SomaLogic
--------------------------------------------------------------------------------

- Q3 revenue $25.4M (down 1% YoY); GAAP net loss $21.0M; Non-GAAP adj. EBITDA -$10.1M.
- Instrument sales grew 14% in Q3, 47% YTD; Non-GAAP gross margin expanded 830bps to 57.0%.
- Operating cash use decreased 53% in Q3 to $12M; cash and investments $129.6M at quarter end.
- Raised 2023 financial outlook; planned merger with SomaLogic cited to enhance revenue and accelerate path to profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000095017023060237/0000950170-23-060237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000095017023060237/lab-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer